Pharmacotherapy of Schizophrenia Flashcards
Key features that define psychotic disorders
- Delusions: fixed false beliefs that are not amenable to change even with conflicting evidence
- Hallucinations-perception-like experiences that occur without external stimulus
- Disorganized thinking and speech-switching from one topic to another, unrelated answers to questions
- Disorganized or abnormal motor behavior
- Negative symptoms
Disease course in Schizophrenia
Onset late adolescence to early adult
Men-late teens, early 20s
Women–late 20s, early 30s
Link to Substance Use
Smoking is associated with induction of 1A2, not due to nicotine, but because of hydrocarbons produced and inhaled, which decreases the serum concentration of 1A2 substrate antipsychotics (olanzapine, asenapine, clozapine, loxapine)
Marijuana, cocaine, and amphetamine use can hasten the onset of schizophrenia, exacerbate symptoms, adn reduce time to relapse
Substance use treatment can be successfully achieved along with mental health treatment with schizophrenia, should be undertaken at the same time
Antipsychotic Drug Therapy overview
Doses per day
Side effects: what will patients tolerate? What are their other disease states?
Previous drug therapy: success or failure? Do family members have this disease?
Cost of drug therapy
Concomitant drug therapy
Need for monitoring: labs? weight? ECG?
Antipsychotic Drug Selection
Oral antipsychotic drug therapy is generally considered first-line, unless the patient presents with reasons to consider IM depot drug therapy first
Typical antipsychotics
Older agents–primarily D2 receptor antagonists
Efficacy for positive symptoms is similar to atypical antipsychotics
Typical antipsychotics clinical pearls
Haloperidol is most commonly used–routine PRN
More EPS with high potency typical–and atypical antipsychotics risperidone and paliperidone
Are very effective for treating the positive symptoms, but are likely to worsen negative and cognitive symptoms
Partial agonists
“stabilize” dopamine transmission–not too much, not too little
Associated with more akathisia than other antipsychotics
Approved for adjunct treatment in depression so all have boxed warning for suicidal thoughts/behavior
Aripiprazole
Partial Agonist
2D6 and 3A4 substrate
Moderate akathisia
Low weight gain
Brexpiprazole
Partial agonist
2D6 and 3A4 substrate
Moderate akathisia
Low-moderate weight gain
Cariprazine
Partial agonist
3A4 substrate
Moderate akathisia
Low-moderate weight gain
Asenapine
Sublingual and patch formulations
1A2 substrate
QTc prolongation
Clozapine
1A2 substrate
Boxed warnings: neutropenia, orthostasis, bradycardia, syncope, seizures, myocarditis, cardiomyopathy
Side effects: sedation, weight gain, constipation, hypersalivation, dry mouth, GI hypomotility with obstruction risk
QTc prolongation
REMS: monitoring timelines weekly x 6 months, biweekly x 6 months, then every 4 weeks
Olanzapine
1A2 substrate
Significant weight gain and sedation
High risk metabolic syndrome
DRESS warning
Quetiapine
3A4 substrate
QTc prolongation
Weight gain and sedation
Boxed warning for suicidal ideation
Asenapine Transdermal Patch
Secuado
Apply 1 patch q24hrs, rotate patch site to minimize application site reactions
Warning for QTc prolongation
UGT and 1A2 substrate–reduce dose of patch if given with strong 1A2 inhibitors
Olanzapine/Samidorphan
Lybalvi
Samidorphan is an opioid antagonist with preferential activity at the mu opioid receptor
Iloperidone
High risk for orthostasis and syncope
QTc prolongation
2D6 substrate